Overview
Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects
Status:
Completed
Completed
Trial end date:
2004-02-01
2004-02-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Boryung Pharmaceutical Co., LtdCollaborator:
Covance
Criteria
Inclusion Criteria:- male of 18-55 years old
- BMI 19-29kg/m2
- subjects in good health
- subjects with written informed consent
Exclusion Criteria:
- subjects with multiple drug allergy or allergy to ARB
- subjects with medication that affect drug absorption or elimination within 30days.
- subjects with orthostatic hypotension of >20mmHg decrease of sbp
- subjects with history of neurologic, liver, renal, GI, CV, psychological or other
major disorder